Beranda › Limfoma Sel B › Florida
Uji klinis Limfoma Sel B di Florida
15 studi untuk Limfoma Sel B mencari peserta di lokasi di Florida.
Kota di Florida
Teks studi resmi (Bahasa Inggris)
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06350318A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- University of California Miami, Sylvester Comprehensive Cancer Center, Miami
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07439653A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines
- Cleveland Clinic Florida, Weston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06742996Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Tampa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06634589A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Miami
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06393738A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Research Site, Jacksonville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07123454Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- University of Miami, Coral Gables
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Florida Cancer Specialists, Fort Myers
- Cancer Specialists of North Florida -St Augustine, Saint Augustine
- Florida Cancer Specialists East, West Palm Beach
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05254743A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Florida, Jacksonville
- AdventHealth, Orlando
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Baptist Health Miami Cancer Institute, Miami
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
- Florida Cancer Specialists, Sarasota
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT05463263The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- ASCLEPES Research Centers, Weeki Wachee
Menerima pesertaFase 1/2
Usia 12 hingga 95 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04329728B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT06191887Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Miami, Miami
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.